Clinical trials: Coeliac Disease
Irritable Bowel Syndrome, Crohn Disease
Effect of UGIR in Adults With Compromised Gut Function and Malabsorption
This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Ulcerative Colitis, Celiac Disease
- Trial name
- NCT03011593
- Testing
- Nutrition Support Product
- Volunteers
- 18 people
- Sponsor
- Metagenics, Inc.
Celiac Disease
Study of DONQ52 in Active Celiac Disease
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in…
- Trial name
- NCT07239336
- Testing
- Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 92 people
- Sponsor
- Chugai Pharmaceutical
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Celiac Disease
Study of Latiglutenase in T1D/CD Patients
This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.
- Trial name
- NCT04839575
- Testing
- Latiglutenase
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Entero Therapeutics
Celiac Disease
Assessment of KAN-101 in Celiac Disease (ACeD)
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2.
- Trial name
- NCT04248855
- Testing
- KAN-101
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Celiac Disease
Safety Study of Larazotide Acetate to Treat Celiac Disease.
To demonstrate the safety, pharmacokinetics and efficacy of larazotide acetate in patients with controlled celiac disease on a gluten-free diet following a gluten challenge.
- Trial name
- NCT00386165
- Testing
- larazotide acetate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
- Trial name
- NCT00620451
- Testing
- larazotide acetate
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 105 people
- Sponsor
- 9 Meters Biopharma, Inc.
Coeliac Disease, Celiac Disease
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a…
- Trial name
- NCT06557772
- Testing
- Amlitelimab, SIGE, Gluten-free product (GFP)
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 229 people
- Sponsor
- Sanofi
Celiac Disease, Gluten Sensitivity
Bovine Colostrum to Prevent Absorption of Gluten
To investigate the use of hyperimmune bovine colostrum to reduce gluten absorption. A double-blind, cross-over study will be performed in which persons who are following a strict gluten-free diet will be challenged with oral…
- Conditions
- Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
- Trial name
- NCT05555446
- Testing
- Bovine colostrum
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Milky Way Life Sciences LLC
Celiac Disease
A Phase II Study of CCX282-B in Patients With Celiac Disease
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
- Trial name
- NCT00540657
- Testing
- CCX282-B
- Where
- Finland
- Volunteers
- 90 people
- Sponsor
- Amgen
Celiac Disease
Effects of a Nutritional Solution to Improve Intestinal Permeability in Celiac Patients
Celiac disease (or gluten intolerance) is recognized as one of the most common chronic diseases: prevalence of 1 in 100 to 1/300 people in Europe and the United States.
- Trial name
- Protalsafe (NCT03483805)
- Testing
- Protalsafe
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Société Guaranteed Gluten Free (GGF)
Celiac Disease
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease
- Trial name
- NCT00889473
- Testing
- Larazotide acetate, Gluten 900 mg
- Where
- 15 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- 9 Meters Biopharma, Inc.
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.
Celiac Disease
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
- Trial name
- NCT00959114
- Testing
- ALV003
- Where
- Finland
- Volunteers
- 74 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease
A randomized, double-blind, placebo-controlled, two treatment, parallel group study to investigate the effects of RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease.
- Trial name
- NCT02679014
- Testing
- RO5459072
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Celiac Disease
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
This study was conducted to evaluate the efficacy of multiple doses of larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge in subjects with celiac disease.
- Trial name
- NCT00492960
- Testing
- larazotide acetate, 900 mg gluten
- Where
- 23 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease
Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease
A randomized, double-blind, placebo-controlled, dose titration trial, stratified by Human Leukocyte Antigen (HLA)-DQ2.5 genotype in subjects with celiac disease.
- Trial name
- NCT02528799
- Testing
- Nexvax2
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 38 people
- Sponsor
- ImmusanT, Inc.
Celiac Disease
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac…
- Trial name
- NCT05425446
- Testing
- DONQ52
- Where
- 21 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.